Urelumab (TNFRSF9/CD137) - Research Grade Biosimilar
Product Specifications
Background
Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb (R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex.
Immunogen
Homo sapiens / TNFRSF9/CD137 [Homo sapiens]
Clonality
Recombinant Monoclonal
Conjugation
Unconjugated
Type
Primary Antibodies, Biosimilars
Source
CHO cells
Field of Research
Cancer
Purification
>95%
Concentration
Batch dependent
Buffer
PBS buffer pH7.5
Modification
None
Shipping Conditions
Blue Ice
Storage Conditions
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.
Product Datasheet
https://www.prosci-inc.com/?datasheet_sku=10-460
Fragment
IgG4-kappa
NCBI Organism
Homo sapiens
Other Product Names
BMS-663513
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
